Red blood cells mediate spontaneous aggregation of platelets in whole blood.
The influence of red blood cells on spontaneous platelet aggregation (SPA) has been studied ex vivo. Platelet aggregation was quantified by measuring the fall in single platelet count using a new whole blood platelet counter. When aliquots of whole blood and autologous platelet rich plasma (PRP) were roller-mixed at 37 degrees C, a marked fall in platelet count occurred in whole blood due to SPA but platelet count remained almost unchanged in PRP. When blood from healthy young controls, aged 20-35 years, was compared with healthy old controls, aged 48-80 years, and patients with thrombotic complications, the extent of SPA was in the order: thrombotic patients greater than old controls greater than young controls. Prostacyclin and the new stable prostacyclin analogue Iloprost, at 8 nM effectively inhibited SPA. 2-Chloroadenosine (10 microM) which is an inhibitor of ADP-induced platelet aggregation was also an effective inhibitor of SPA. Acetylsalicylic acid (56 microM) and the thromboxane A2 receptor blocker BM13.177 (0.5 microM) only partially inhibited SPA. ADP from red blood cells is suspected to mediate red cell-induced SPA. However, the possibility that the red cells have an important physical role in SPA cannot be ruled out.
D015762:2-Chloroadenosine; D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000328:Adult; D000368:Aged; D001241:Aspirin / Q000494:pharmacology; D011464:Epoprostenol / Q000494:pharmacology; D004912:Erythrocytes / Q000502:physiology*; D006801:Humans; D016285:Iloprost; D066298:In Vitro Techniques; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count; D013449:Sulfonamides / Q000494:pharmacology; D013927:Thrombosis / Q000097:blood
D013449:Sulfonamides; D015762:2-Chloroadenosine; C040624:sulotroban; D011464:Epoprostenol; D016285:Iloprost; D000241:Adenosine; D001241:Aspirin